Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys.

[1]  K. To,et al.  Triple combination of FDA-approved drugs including flufenamic acid, clarithromycin and zanamivir improves survival of severe influenza in mice , 2018, Archives of Virology.

[2]  Tokiko Watanabe,et al.  A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets. , 2017, Cell host & microbe.

[3]  Xiang-rong Zhao,et al.  Genesis and Spread of Newly Emerged Highly Pathogenic H7N9 Avian Viruses in Mainland China , 2017, Journal of Virology.

[4]  Catherine S. K. Cheung,et al.  Anti‐inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial , 2017, Antiviral research.

[5]  A. Tam,et al.  Efficacy of Clarithromycin‐Naproxen‐Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open‐label Randomized, Controlled, Phase IIb/III Trial , 2017, Chest.

[6]  Y. Sakoda,et al.  Comparison of pathogenicities of H7 avian influenza viruses via intranasal and conjunctival inoculation in cynomolgus macaques. , 2016, Virology.

[7]  H. Suzaki,et al.  Past, present and future of macrolide therapy for chronic rhinosinusitis in Japan. , 2016, Auris, nasus, larynx.

[8]  Y. Sakoda,et al.  Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates , 2015, Antimicrobial Agents and Chemotherapy.

[9]  H. Kubo,et al.  Additional treatment with clarithromycin reduces fever duration in patients with influenza. , 2014, Respiratory investigation.

[10]  Y. Kawaoka,et al.  Efficacy of Repeated Intravenous Administration of Peramivir against Highly Pathogenic Avian Influenza A (H5N1) Virus in Cynomolgus Macaques , 2014, Antimicrobial Agents and Chemotherapy.

[11]  H. Kitano,et al.  Disease Severity Is Associated with Differential Gene Expression at the Early and Late Phases of Infection in Nonhuman Primates Infected with Different H5N1 Highly Pathogenic Avian Influenza Viruses , 2014, Journal of Virology.

[12]  Y. Kawaoka,et al.  Protective Efficacy of Passive Immunization with Monoclonal Antibodies in Animal Models of H5N1 Highly Pathogenic Avian Influenza Virus Infection , 2014, PLoS pathogens.

[13]  K. Yanagihara,et al.  Efficacy of Combination Therapy with Oseltamivir Phosphate and Azithromycin for Influenza: A Multicenter, Open-Label, Randomized Study , 2014, PloS one.

[14]  Y. Kawaoka,et al.  Protection against H5N1 Highly Pathogenic Avian and Pandemic (H1N1) 2009 Influenza Virus Infection in Cynomolgus Monkeys by an Inactivated H5N1 Whole Particle Vaccine , 2013, PloS one.

[15]  S. Kudoh,et al.  Use of macrolides in the 2009 H1N1 virus infection outbreak: a survey of general practices in Japan. , 2013, Respiratory investigation.

[16]  H. Kido,et al.  Immunomodulator Clarithromycin Enhances Mucosal and Systemic Immune Responses and Reduces Re-Infection Rate in Pediatric Patients with Influenza Treated with Antiviral Neuraminidase Inhibitors: A Retrospective Analysis , 2013, PloS one.

[17]  Noriko Kishida,et al.  Characterization of H7N9 influenza A viruses isolated from humans , 2013, Nature.

[18]  Takashi Suzuki,et al.  Influenza virus utilizes N-linked sialoglycans as receptors in A549 cells. , 2013, Biochemical and biophysical research communications.

[19]  M. Imai,et al.  Characterization of neuraminidase inhibitor‐resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post‐pandemic periods in Japan , 2013, Influenza and other respiratory viruses.

[20]  Jie Dong,et al.  Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. , 2018 .

[21]  Semicyuc,et al.  Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia , 2013, Intensive Care Medicine.

[22]  H. Kido,et al.  Oral Clarithromycin Enhances Airway Immunoglobulin A (IgA) Immunity through Induction of IgA Class Switching Recombination and B-Cell-Activating Factor of the Tumor Necrosis Factor Family Molecule on Mucosal Dendritic Cells in Mice Infected with Influenza A Virus , 2012, Journal of Virology.

[23]  H. Mukae,et al.  Clarithromycin has limited effects in non-elderly, non-severe patients with seasonal influenza virus A infection. , 2012, The Journal of infection.

[24]  Eiryo Kawakami,et al.  Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Yukiko Muramoto,et al.  Pathogenicity of highly pathogenic avian H5N1 influenza A viruses isolated from humans between 2003 and 2008 in northern Vietnam , 2010, The Journal of general virology.

[26]  Ryo Takano,et al.  Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses , 2010, PLoS pathogens.

[27]  B. Rubin,et al.  Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications , 2010, Clinical Microbiology Reviews.

[28]  L. Gubareva,et al.  Detection of E119V and E119I Mutations in Influenza A (H3N2) Viruses Isolated from an Immunocompromised Patient: Challenges in Diagnosis of Oseltamivir Resistance , 2010, Antimicrobial Agents and Chemotherapy.

[29]  R. Nagatomi,et al.  Clarithromycin Inhibits Type A Seasonal Influenza Virus Infection in Human Airway Epithelial Cells , 2010, Journal of Pharmacology and Experimental Therapeutics.

[30]  H. Togari,et al.  Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza , 2009, Respirology.

[31]  R. Nagatomi,et al.  Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells. , 2009, Antiviral research.

[32]  D. Kelvin,et al.  Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains. , 2009, Journal of infection in developing countries.

[33]  Lynnette Brammer,et al.  Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. , 2009, JAMA.

[34]  R. Wunderink,et al.  Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia , 2009, European Respiratory Journal.

[35]  C. Roussos,et al.  Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  J. Rello,et al.  Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock* , 2007, Critical care medicine.

[37]  Yoshihiro Kawaoka,et al.  oseltamivir: descriptive study , 2022 .

[38]  E. Gabazza,et al.  In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. , 2003, American journal of respiratory and critical care medicine.

[39]  S. Ishizuka,et al.  Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells. , 2002, American journal of respiratory and critical care medicine.

[40]  T. Fukui,et al.  Effect of maclorides on duration and resolution of symptoms and complication of pneumonia in children with influenza. , 2002, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[41]  S. Kudoh,et al.  Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. , 1998, American journal of respiratory and critical care medicine.

[42]  H. Maeda,et al.  Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. , 1998, American journal of respiratory and critical care medicine.

[43]  M. Rosenthal,et al.  Long-term azithromycin may improve lung function in children with cystic fibrosis , 1998, The Lancet.